Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rilonacept · Arcalyst, KPL-914

Fusion protein · Antagonist of Interleukin-1 alpha (IL1A) and Interleukin-1 beta (IL1B) · developed by Kiniksa Pharmaceuticals

Approved FDA, Feb 2008
KNSA Developer
2 Registered trials

What is Rilonacept?

Rilonacept is a soluble decoy receptor that binds interleukin-1 alpha and interleukin-1 beta, preventing them from engaging cell surface IL-1 receptors, and also binds IL-1 receptor antagonist. It is used in cryopyrin-associated periodic syndromes, deficiency of IL-1 receptor antagonist, and recurrent pericarditis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Arcalyst, KPL-914
Drug type
Fusion protein
Targets
Interleukin-1 alpha (IL1A), Interleukin-1 beta (IL1B), Interleukin-1 receptor antagonist (IL1RN) (secondary target)
Mechanism
Antagonist of Interleukin-1 alpha (IL1A) and Interleukin-1 beta (IL1B)
Pathways
IL-1 receptor signaling, NLRP3 inflammasome activation
Therapy area
Cardiovascular
Developer
Kiniksa Pharmaceuticals, Ltd. (KNSA)
FDA status
Approved as Arcalyst (February 27, 2008), BLA125249 · FDA label
UNII
8K80YB5GMG

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 16, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03737110 Phase 3 Recurrent Pericarditis Completed KNSA
NCT03980522 Phase 2 Recurrent Pericarditis Completed KNSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Recurrent Pericarditis

Other drugs acting on IL1A / IL1B

More from Kiniksa Pharmaceuticals

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KNSA page.

Follow KNSA, the company behind Rilonacept

See KNSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KNSA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.